Company: UHS
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0000950170-25-027785
Chunk: 157

Company: UNIVERSAL HEALTH SERVICES INC
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1B
Chunk 157
---
 sales outstanding as of December 31, 2024, as compared to December 31, 2023, as discussed below;    

•a favorable change of $94 million from other working capital accounts due primarily to the timing of disbursements for certain accrued liabilities;  

•an unfavorable change of $61 million in other assets and deferred charges;

•a favorable change of $56 million in accrued and deferred income taxes, and; 

•$12 million of other combined net unfavorable changes. 

Days sales outstanding (“DSO”):  Our DSO are calculated by dividing our net revenue by the number of days in the year. The result is divided into the accounts receivable balance at the end of the year. Our DSO were 50 days at December 31, 2024 and 57 days at December 31, 2023. 

68

Net cash used in investing activities

Net cash used in investing activities was $911 million during 2024 and $763 million during 2023.

2024:

The $911 million of net cash used in investing activities during 2024 consisted of:

•$944 million spent on capital expenditures including capital expenditures for equipment, renovations and new projects at various existing facilities;

•$39 million of proceeds received from sales of assets and businesses;

•$19 million spent on the acquisition of businesses and property, and;

•$13 million received in connection with net cash inflows from forward exchange contracts that hedge our investment in the U.K. against movements in exchange rates;

2023:

The $763 million of net cash used in investing activities during 2023 consisted of:

•$743 million spent on capital expenditures including capital expenditures for equipment, renovations and new projects at various existing facilities;

•$41 million paid in connection with net cash outflows from forward exchange contracts that hedge our investment in the U.K. against movements in exchange rates;

•$24 million of proceeds received from sales of assets and businesses, and;

•$4 million spent on the acquisition of businesses and property. 

Net cash used in financing activities

Net cash used in financing activities was $1.145 billion during 2024 and $494 million during 2023.

2024:

The $1.145 billion of net cash used in financing activities during 2024 consisted of the following:

•spent $2.640 billion on net repayments of debt as follows: (i) $2.259 billion related to our previous tranche A term loan facility which was extinguished in